Search NLS News

Immedica Pharma and Japanese company OrphanPacific entered an agreement under which OrphanPacific gains the exclusive rights to Ravicti in Japan. The pharmaceutical drug product Ravicti is approved in Europe and North America for treatment of urea cycle disorders (UCD). Under the announced partnership, OrphanPacific is granted a license to develop, register and commercialize the product […]

Capitainer has closed a share issue to capitalize on growing interest in home-sampling with its new qDBS dried blood spot testing system. The investment round, led by Sciety, brought in both existing and new industry specialist investors and several board members and the CEO. “Once again we are delighted to have secured such strong support […]

The 18th edition of the Anglonordic Life Science Conference offered an exclusive opportunity for European investors and R&D companies from the Nordics and the UK to connect with each other. The conference took place on Thursday 5th May at etc.venues County Hall, London, but networking began already on the evening of Wednesday 4th May, with […]

This initiative aims to provide all of Pfizer’s patented medicines and vaccines available in the US or the European Union on a not-for-profit basis to 1.2 billion people in 45 lower-income countries. The Accord seeks to greatly reduce the health inequities that exist between many lower-income countries and the rest of the world, Pfizer states. […]

Valur Ragnarsson has been appointed as Chairman of the Board by Coripharma’s Board of Directors. Valur is a pharmaceutical executive with a solid track record spanning over 30 years, driving financial results and sustainable growth in the global generic pharmaceutical industry, describes the company. Valur Ragnarsson Valur has been a part of Coripharma’s Board of […]

The purpose of this memorandum of understanding (MoU) is to promote cooperation between the participants across local, regional and national healthcare, research and innovation systems in support of the development of dynamic, effective and attractive life science ecosystems. The participants will continue to pursue opportunities that advances in medical technologies and techniques enable to benefit […]

AlzeCure Pharma has received approval from the regulatory authorities in Sweden to initiate its clinical phase IIa study with the drug candidate ACD440 in patients with peripheral neuropathic pain. ”We now have all regulatory approvals in place to be able to start the phase IIa study with ACD440. We expect to be able to initiate […]

Xbrane Biopharma has withdrawn the BLA (Biologics License Application) for its investigational biosimilar candidate to Lucentis after receiving feedback from the FDA that complementary information is required for the FDA to take the decision to accept the BLA and initiate the review. Xbrane will receive more information about the requested complementary information from the FDA […]

The analysis shows how the life science cluster is continuing to grow and highlights challenges of finding expertise in STEM subjects and making health data available for the development of new, innovative solutions. The analysis [prepared by Øresundsinstituttet as part of the Interregproject Greater Copenhagen Life Science Analysis Initiative] also shows that the cluster is larger […]

Alvotech and Oaktree Acquisition Corp II establish financing facilities to enhance the company’s capital position and to replace any redeemed capital as part of their proposed merger. The two parties agree to reduce the minimum cash condition outlined in the merger agreement, thereby enhancing deal certainty in their proposed business combination. In late 2021, Alvotech […]